Protego Biopharma Inc. and Scripps Research Institute have identified serine/threonine kinase/endoribonuclease IRE1 (ERN1) activators reported to be useful for the treatment of diabetes, myocardial infarction, nonalcoholic fatty liver disease (NAFLD), Parkinson's disease, retinal degeneration, atherosclerosis, Gaucher disease and Alzheimer's disease, among others.
Unnatural Products Inc. has synthesized cell-permeable cyclic peptides acting as E3 ubiquitin-protein ligase Mdm2 (Hdm2) and/or Mdm4 (Mdmx) inhibitors reported to be useful for the treatment of cancer.
Biocryst Pharmaceuticals Inc. has disclosed imidazole derivatives acting as activin receptor-like kinase 2 (ALK-2; ActR-IA) inhibitors reported to be useful for the treatment of diffuse intrinsic pontine glioma, spondyloarthritis and fibrodysplasia ossificans progressiva.
Medshine Discovery Inc. has divulged benzospiroheterocyclic derivatives acting as prostaglandin E receptor 4 (PTGER4; EP4 receptor) antagonists reported to be useful for the treatment of cancer.
Glycomimetics Inc. has identified glycosides acting as galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, inflammation, thrombosis, cardiovascular disorders, transplant rejection, neurodegeneration, fibrosis and liver diseases, among other disorders.
Hibercell Inc. has disclosed aminopyrimidine derivatives acting as phosphatidylinositol 5-phosphate 4-kinase type II α (PIP4K2A; PIP5K2A) and type II β (PIP4K2B; PIP5K2B) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, inflammation and metabolic diseases.
RSS